Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
130 hedge funds and large institutions have $196M invested in Lumos Pharma, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 25 closing their positions.
111% more call options, than puts
Call options by funds: $6.83M | Put options by funds: $3.24M
65% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 26
24% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 25
3% more funds holding
Funds holding: 126 → 130 (+4)
1% less capital invested
Capital invested by funds: $199M → $196M (-$2.52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$18.3M |
| 2 |
Millennium Management
New York
|
+$9.64M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$7.79M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$7.31M |
| 5 |
BlackRock
New York
|
+$3.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$8.46M |
| 2 |
CCI
Columbus Circle Investors
|
-$4.95M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$3.88M |
| 4 |
PP
PDT Partners
New York
|
-$3.56M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.82M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NFA
151
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$131K | -1,426 | Closed |
|
|
OC
152
Oppenheimer & Co
New York
| – | -$114K | -1,244 | Closed |
|
153
Capital Fund Management (CFM)
Paris,
France
| – | -$108K | -1,178 | Closed |
|
|
PCM
154
Prelude Capital Management
New York
| – | -$32K | -344 | Closed |
|
|
WAM
155
Wolverine Asset Management
Chicago,
Illinois
| – | -$83 | -1 | Closed |
|
LUMO Hedge Fund Activity: Q4 2017 in Review
130 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2017, worth a combined $196M — down 1.3% from $199M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new LUMO positions and 25 closed out — a net gain of 6 holders — while 43 added to existing stakes and 26 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $18.3M. The largest seller was OrbiMed, exiting entirely with an estimated $8.46M sold.
- 130 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2017, up from 126 in Q3 2017.
- Funds reported $196M of Lumos Pharma, Inc. Common Stock stock for Q4 2017, down 1.3% quarter-over-quarter.
- 31 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2017 and 25 closed out, a net change of +6 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2017 was Great Point Partners, an estimated $18.3M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q4 2017 was OrbiMed, an estimated $8.46M sold.
Based on aggregated 13F filings for Q4 2017.